Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Truveris
company
About
Truveris is a technology company driving transparency, access and lower costs across the prescription drug ecosystem.
- 101 - 250
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $3.80M
- Industries
- Health Care,Information Technology,SaaS,Wellness
- Founded date
- Jan 1, 2009
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Truveris brings transparency to the prescription drug ecosystem through data-driven innovations. Truveris’ platform offers customers – from the individual patient to employers, retailers, pharmacy benefits stakeholders, and manufacturers – the data and insights they need to effectively and efficiently manage rising costs and market access challenges. Based in Manhattan, Truveris is backed by Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round Capital.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$3.80M
Truveris has raised a total of
$3.80M
in funding over 2 rounds. Their latest funding was raised on
Feb 1, 2011 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 1, 2011 | Series A | $3.80M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Truveris is funded by 1 investors.
GSA Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
GSA Venture Partners
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
